IL2 and melanoma: This is supported by experiments with mouse tumor models indicating that the administration of IL-2Rα-biased IL2ICx [32] or IL-2-IL-2Rα fusion protein preferentially stimulating IL-2Rα+ cells [33] can induce the potent antitumor activity of CD8+ T cells (B16F10 melanoma in C57BL/6 mice; and BCL1 leukemia and CT26 colon carcinoma in BALB/C mice) [3,34].